Progression of steroid-associated osteoporosis after heart transplantation

Ann Thorac Surg. 1999 Jan;67(1):130-3. doi: 10.1016/s0003-4975(98)01040-6.

Abstract

Background: Osteoporosis has been recognized as an important side effect of long-term and of pulsed steroid application after heart transplantation.

Methods: In June 1989 a prospective clinical trial was started to study bone demineralization by quantitative computed tomographic scan. All patients received vitamin D and calcium. In group I (n = 30) synthetic calcitonin (40 Medical Research Council Standard Units subcutaneously per day was administered in 14-day cycles, whereas group II patients (n = 31) received a placebo preparation. Repeat trabecular and cortical quantitative computed tomographic scans of the thoracic (T12) and lumbar spine (L1, L2, L3) were obtained within 48 weeks after heart transplantation.

Results: Expressed as the means of T12, L1, L2, and L3, trabecular bone density decreased significantly from 100+/-24 to 79+/-29 mg/mL within 3 weeks after heart transplantation, followed by a further reduction to 67+/-29 mg/mL after 3 months in the calcitonin group. The values for cortical bone density decreased significantly from 229+/-37 to 202+/-40 mg/mL (calcitonin) 3 weeks after heart transplantation. Comparable results were obtained in the placebo group. In both groups bone density remained stable thereafter. Intergroup differences were not of statistical significance.

Conclusions: In heart transplant recipients progressive trabecular bone demineralization is limited to the first 3 postoperative months. Thereafter, bone density remained stable. A positive effect of synthetic calcitonin in addition to prophylactic calcium and vitamin D application could not be proved by repeat quantitative computed tomography.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / adverse effects*
  • Bone Density
  • Calcitonin / therapeutic use
  • Disease Progression
  • Double-Blind Method
  • Female
  • Heart Diseases / surgery
  • Heart Transplantation*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Osteoporosis / chemically induced*
  • Postoperative Complications*
  • Prednisone / adverse effects*
  • Prospective Studies
  • Time Factors
  • Tomography, X-Ray Computed / methods

Substances

  • Anti-Inflammatory Agents
  • Immunosuppressive Agents
  • Calcitonin
  • Prednisone